Retrospective Study of Nephrotoxicity Rate among Adult Patients Receiving Colistin Compared to β-lactam Antibiotics
Abdul Ghafur, Nitin Bansal, Vidyalakshmi Devarajan, T Raja, Jose Easow, MA Raja, Sankar Sreenivas, Balasubramaniam Ramakrishnan, SG Raman, Dedeepiya Devaprasad, Ramesh Nimmagadda
Carbapenem resistance, Colistin nephrotoxicity, Risk of renal dysfunction, injury to the kidney, failure of kidney function, loss of kidney function, end-stage kidney disease score
Citation Information :
Ghafur A, Bansal N, Devarajan V, Raja T, Easow J, Raja M, Sreenivas S, Ramakrishnan B, Raman S, Devaprasad D, Nimmagadda R. Retrospective Study of Nephrotoxicity Rate among Adult Patients Receiving Colistin Compared to β-lactam Antibiotics. Indian J Crit Care Med 2019; 23 (11):518-522.
Purpose: Patients receiving colistin for carbapenem-resistant gram-negative bacteria (CR-GNB) infections generally have multiple risk factors for nephrotoxicity, so it might be possible that colistin may be erroneously blamed for the nephrotoxicity.
Materials and methods: We retrospectively analyzed case records of patients who received colistin and those who received antibiotics other than colistin [carbapenem or β-lactam–β-lactamases inhibitors (βL–βLI)] for gram-negative bacteremia. Those patients with preexisting renal failure and those who received antibiotics for <72 hours were excluded from the study. Nephrotoxicity was assessed using the risk of renal dysfunction, injury to the kidney, failure of kidney function, loss of kidney function, end-stage kidney disease (RIFLE) criteria.
Results: Out of the 222 patients, the colistin arm had 118 and the noncolistin arm had 104 patients. Even though the colistin arm had significantly higher number of sicker patients with neutropenia (40.7% vs 14.4%, p = 0.0001), mechanical ventilation (0.0001), having lines (0.0001), on inotropes (0.003), receiving other nephrotoxic drugs (0.0001), and higher Pitt score (p = 0.0001), there was no significant difference in the nephrotoxicity between the two arms (10.2% vs 9.6%, p = 0.89). Logistical regression showed a higher Pitt bacteremia score (p = 0.03) and a higher Charlson comorbidity index (p = 0.02), but not colistin administration (p = 0.32), were independently associated with nephrotoxicity.
Conclusion: Administration of colistin was not associated with higher rates of nephrotoxicity than carbapenems or βL–βLI agents.
Xu Y, Gu B, Huang M, Liu H, Xu T, Xia W, et al. Epidemiology of carbapenem resistant Enterobacteriaceae (CRE) during 2000–2012 in Asia. J Thorac Dis 2015;7(3):376–385. DOI: 10.3978/j.issn.2072-1439.2014.12.33.
Hsu L-Y, Apisarnthanarak A, Khan E, Suwantarat N, Ghafur A, Tambyah PA. Carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia. Clin Microbiol Rev 2017;30(1):1–22. DOI: 10.1128/CMR.00042-16.
Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995;273(2):117–123. DOI: 10.1001/jama.1995.03520260039030.
Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011;1(1):14. DOI: 10.1186/2110-5820-1-14.
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, the Acute Dialysis Quality Initiative Workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the acute dialysis quality initiative (ADQI) group. Crit Care 2004;8(4):R204–R212. DOI: 10.1186/cc2872.
Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis 2017;17(7):726–734. DOI: 10.1016/S1473-3099(17)30228-1.
Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram negative bacterial infections. Lancet Infect Dis 2006;6(9):589–601. DOI: 10.1016/S1473-3099(06)70580-1.
Doshi NM, Mount KL, Murphy CV. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy 2011;31(12):1257–1264. DOI: 10.1592/phco.31.12.1257.
Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010;35(2):194–199. DOI: 10.1016/j.ijantimicag.2009.10.005.
Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug resistant Gram-negative bacterial infections. Int J Antimicrob Agents 2010;35(3):297–300. DOI: 10.1016/j.ijantimicag.2009.11.016.
Kim J, Lee K-H, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents 2009;34(5):434–438. DOI: 10.1016/j.ijantimicag.2009.06.028.
Ghafur A, Gohel S, Devarajan V, Raja T, Easow J, Raja MA, et al. Colistin nephrotoxicity in adults: single center large series from India. Indian J Crit Care Med 2017;21(6):350–354. DOI: 10.4103/ijccm.IJCCM_140_17.
Lopes JA, Jorge S, Resina C, Santos C, Pereira A, Neves J, et al. Acute renal failure in patients with sepsis. Crit Care 2007;11(2):411. DOI: 10.1186/cc5735.
Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004;351(2):159–169. DOI: 10.1056/NEJMra032401.
Lewis JR, Lewis SA. Colistin interactions with the mammalian urothelium. Am J Physiol Cell Physiol 2004;286(4):C913–C922. DOI: 10.1152/ajpcell.00437.2003.
Hartzell JD, Neff R, Ake R, Howard R, Olson S, Paolino K, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009;48(12):1724–1728. DOI: 10.1086/599225.
Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011;53(9):879–884. DOI: 10.1093/cid/cir611.
Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007;11(5):402–406. DOI: 10.1016/j.ijid.2006.09.011.
Sabuda DM, Laupland K, Pitout J, Dalton B, Rabin H, Louie T, et al. Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol 2008;19(6):413–418. DOI: 10.1155/2008/743197.
Bagshaw SM, Lapisky S, Dial S, Arabi Y, Dodek P, Wood G, et al. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med 2009;35(5):871–881. DOI: 10.1007/s00134-008-1367-2.
Rocco M, Montini L, Alessandri E, Venditti M, Laderchi A, De Pascale G, et al. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care 2013;17(4):R174. DOI: 10.1186/cc12853.
Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil AC. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012;54(5):670–680. DOI: 10.1093/cid/cir934.
Garzotto F, Piccinni P, Cruz D, Gramaticopolo S, Dal Santo M, Aneloni G, et al. RIFLE-based data collection/management system applied to a prospective cohort multicenter Italian study on the epidemiology of acute kidney injury in the intensive care unit. Blood Purif 2011; 31(1–3):159–171. DOI: 10.1159/000322161.
Paul M, Bishara J, Levcovich A, Chowers M, Goldberg E, Singer P, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 2010;65(5):1019–1027. DOI: 10.1093/jac/dkq069.
Desai K, Kazi M, Ajbani K, Munshi M, Rodrigues C, Soman R, et al. Clinical outcomes and safety of colistin in treatment of Gram negative infections: a prospective observational study. Egypt J Crit Care Med 2016;4:67–72. DOI: 10.1016/j.ejccm.2016.07.001.
Dewan A, Shoukat M. Evaluation of risk of nephrotoxicity with high dose, extended-interval colistin administration. Indian J Crit Care Med 2014;18(7):427–430. DOI: 10.4103/0972-5229.136070.